Deutsche Bank Maintains Buy on Bio-Techne, Lowers Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Justin Bowers maintains a Buy rating on Bio-Techne (NASDAQ:TECH) but lowers the price target from $85 to $82.
April 18, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Deutsche Bank maintains a Buy rating on Bio-Techne, but lowers the price target from $85 to $82.
The adjustment in price target by a major bank like Deutsche Bank, while maintaining a Buy rating, suggests a slight recalibration of expectations rather than a fundamental shift in the company's outlook. This could lead to short-term price adjustments as the market digests the new target, but the maintained Buy rating indicates continued confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100